Press Room

4th European Conference on Pharmaceutics

Start
Monday, March 20, 2023 - 09:00
End
Tuesday, March 21, 2023 - 17:00
Location: Marseille, France
Booth Number: Panel nr: 56
Hovione presentation with Ana Costa about recent advances in ASD formulations at the 4th European Conference on Pharmaceuticals in Marseille, France | Hovione

HOVIONE PRESENTATION

 

Abstract: “Recent advances in ASD formulations: Dispersome® as alternative carrier in a high-throughput screening setup”

 

Presenter: Ana Costa, Modelling & PAT Scientist at Hovione
Date: Monday, March 20th, 2023
Session: Bioavailability, absorption enhancement and in-vitro/In-vivo correlations 
Panel number: 56

 

 

Contact us to learn more about Dispersome® 

By increasing drug solubility, the Dispersome® platform aims at improving oral bioavailability and therapeutic outcomes for patients. Dispersome® formulations are compatible with standard pharmaceutical processes and Spray Drying provides a scalable manufacturing solution.

Dispersome® is now part of ASD-HIPROS the most advanced and accurate screening tool to identify the best Amorphous Solid Dispersion formulations by Spray Drying.

 

Schedule a meeting with our experts.

schedule a meeting



 

 

 

 

Find more about the 4th European Conference on Pharmaceutics.

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026